Related Experiment Videos
[Chelating therapy in beta-thalassemia]
Insights
Desferrioxamine (DF) effectively manages iron overload in transfusion-dependent thalassemia major patients. Subcutaneous DF administration helps achieve iron balance with no significant adverse effects observed.
Area of Science:
- Hematology
- Pediatrics
- Pharmacology
Background:
- Iron overload is a primary cause of mortality in thalassemia major and other congenital anemias.
- Organ damage, particularly in the liver, endocrine glands, and heart, results from iron overload.
- Desferrioxamine (DF) is the established treatment for iron chelation therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of desferrioxamine (DF) in managing iron overload in beta-thalassemia major and intermedia patients.
- To assess the impact of subcutaneous DF administration on iron balance in young thalassemia major patients.
Main Methods:
- Subcutaneous administration of desferrioxamine (DF) at a dosage of 40 mg/kg/day.
- Monitoring iron balance in patients with thalassemia major.
- Clinical assessment and periodic slit-lamp examinations for ocular alterations in treated subjects.
Main Results:
- Subcutaneous DF administration (40 mg/kg/day) achieved iron-negative balance in thalassemia major patients from three years of age.
- No significant adverse effects were reported during the study.
- Ocular examinations revealed no alterations in 35 evaluated subjects.
Conclusions:
- Subcutaneous desferrioxamine (DF) is an effective and safe treatment for iron overload in transfusion-dependent beta-thalassemia major.
- Patients with thalassemia intermedia also experience iron overload due to increased absorption, necessitating early intervention to reduce iron absorption and prevent complications.
Abstract:
The iron overload is the most common cause of death among transfusion dependent subjects affected by thalassemia major and other congenital anemias. The lesions caused by iron overload are found especially in liver, endocrine glands and heart. Among the various drugs able to remove the iron excess from the organs, desferrioxamine (DF) remains the only one used. The Authors report their experience with this drug in beta-thalassemia major and in beta-thalassemia intermedia patients. The results demonstrate that the subcutaneous administration of DF (40 mg/kg/die) is able to take the patients with thalassemia major in iron negative balance since their third year of life. No important untoward effects are reported. Periodic check with slit lamp has revealed no ocular alteration in 35 subjects. In thalassemia intermedia there is also iron overload due to increased iron absorption. It is probable that these patients too can present the same alterations observed in transfusion dependent beta-thalassemia omozygotes. In order to prevent these lesions it will be necessary to reduce iron absorption since early childhood.